Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29490180 | 1.00 | AKT1 (0.39) | AKT1CYP11B1CYP11B2HTTSMN1; SMN2 | |
| SCHEMBL22862827 | 0.93 | CYP11B1 (0.40) | AKT1CYP11B1CYP11B2HTTSMN1; SMN2 | |
| SCHEMBL29490170 | 0.93 | CYP11B1 (0.40) | AKT1CYP11B1CYP11B2HTTSMN1; SMN2 | |
| SCHEMBL22862467 | 0.82 | HTT (0.43) | CYP11B1CYP11B2HTTSMN1; SMN2MAPK1 | |
| SCHEMBL22862547 | 0.79 | POLB (0.49) | HTTSMN1; SMN2MAPK1LMNA | |
| SCHEMBL29490210 | 0.79 | POLB (0.49) | HTTSMN1; SMN2MAPK1LMNA | |
| SCHEMBL22862437 | 0.78 | CDK9 (0.40) | CYP11B1CYP11B2HTTSMN1; SMN2MAPK1 | |
| SCHEMBL22862544 | 0.78 | PDE2A (0.41) | CYP11B1CYP11B2HTTSMN1; SMN2LMNA | |
| SCHEMBL22862932 | 0.77 | RAD52 (0.32) | DPP4 | |
| SCHEMBL24704178 | 0.75 | HDAC1 (0.35) | CYP11B1CYP11B2HTTSMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389028-A1 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY | 2022-12-08 | — | — | US | disclosed |
| WO-2021002986-A2 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389028-A1 | BAX INHIBITORS AND USES THEREOF | BAX, TMBIM6, BCL2 | AKT1 237/4885CYP11B1 715/4885CYP11B2 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.